Last Updated: July 2025 (Pharma Sector (in India and World))

Pharma Sector (in India and World)
This article deals with the ‘Semi-Conductor Industry (in India and World).’ This is part of our series on ‘Geography’, which is an important pillar of the GS-1 syllabus. For more articles, you can click here.
Link with UPSC Syllabus
- Geography (GS1): Industrial location factors, resource distribution
- Economy (GS3): Manufacturing, exports, employment
- Sci-Tech (GS3): Biotech, IP, pharma innovation
- International Relations (GS2): Health diplomacy, soft power
Introduction
Every morning, when millions of Indians swallow a pill for blood pressure, diabetes, or fever, they rarely stop to wonder—where was this medicine made? How did a factory in Baddi (Himachal) or Hyderabad (Telangana) become a global hub for life-saving drugs?
The answer lies in a complex interplay of geographical, economic, and policy factors that make India the ‘Pharmacy of the World’.
Why Do Pharma Industries Locate Where They Do?
1. Proximity to R&D
- Pharmaceutical manufacturing is science-intensive. R&D is crucial for developing new drugs, vaccines, and biosimilars.
- For instance
- Indian companies like Sun Pharma, Dr. Reddy’s, Biocon invest in in-house R&D, often in Hyderabad, Bengaluru, and Pune.
- Switzerland (Basel) thrives due to investment in biotech and R&D (Novartis, Roche HQs).
2. Availability of Raw Materials and APIs
- Pharmaceutical production requires a large number of Active Pharmaceutical Ingredients (APIs) and chemical intermediates. Active Pharmaceutical Ingredients (APIs) are the “active” part of any medicine.
- China’s Hebei and Jiangsu provinces dominate global API production due to cheap chemical inputs and scale.
- Earlier, India imported ~70% of APIs, mostly from China. But now, India is shifting to self-reliance in API manufacturing, e.g.,:
- Vizag (Andhra Pradesh) → API cluster under PLI scheme
- Solan (Himachal Pradesh) → Bulk drug park
3. Availability of Skilled Manpower
- Pharma requires chemists, biotechnologists, clinical researchers, and data analysts.
- For instance
- Boston (USA) and Cambridge (UK) excel due to presence of world-class universities (Harvard, MIT, Oxford).
- India has 20% of the world’s pharma engineers, with institutes like NIPER, BITS Pilani, and IITs producing talent.
4. Transport and Export Facilities
- Pharma requires:
- Quick supply to hospitals, chemists
- Cold chain for vaccines and sensitive drugs
- Ports and airports for export
- Preferred Zones:
- Mumbai-Pune-Navi Mumbai belt – Access to JNPT port
- Ahmedabad – Linked to Kandla port and roadways
- New Jersey (USA) and Hamburg (Germany) have port access for global exports.
5. Regulatory Environment and Government Policy
- Pharma industry is tightly regulated. Ease of approvals, IP laws, and export-import policies matter.
- For Example
- Ireland and Netherlands attract pharma MNCs due to low taxes and business-friendly laws.
- Belgium is known for its rapid drug approval systems.
- Baddi (Himachal) – low land cost + tax holidays
- In India, schemes like Pharma PLI Scheme, Bulk Drug Parks and 100% FDI via Automatic Route are aimed at promoting pharma sector.
6. Cluster Effect
- Presence of supporting industries like packaging, chemicals, logistics, and contract research creates economies of scale.
- Examples include
- Silicon Valley model applied to pharma in Boston and Basel.
- Hyderabad Pharma City: World’s largest integrated pharma cluster under development.
7. Water and Power Requirements
- Pharma plants require ultra-clean water and uninterrupted electricity for chemical processing, sterilization, and cleanroom operations.
- Example:
- Many API parks are located in coastal Andhra Pradesh (e.g., Vizag) due to water availability.
- Singapore: Biopolis cluster provides reliable utilities with centralized wastewater treatment
8. Market Access & Proximity to Healthcare Hubs
- Pharma industries tend to locate near urban health ecosystems to supply to hospitals, get real-world data, and conduct clinical trials.
- Example:
- Mumbai, Hyderabad, and Delhi-NCR — access to super-specialty hospitals, diagnostic labs, and testing infrastructure.
- New Jersey/NYC corridor — world’s densest hospital-Pharma-R&D ecosystem
Global Pharma Industry

United States – World Leader
- Presence of global pharma giants like Pfizer, Johnson & Johnson, Merck
- Ivy League and top research universities (Harvard, MIT)
- Strong IP protection and venture capital ecosystem
- Note: The US leads in new drug discovery and biotech research, not just generics
Switzerland – Precision Pharma
- Presence of global pharma giants like Novartis and Roche
- Swiss pharma is highly innovation and research-intensive—often setting global standards.
- Strict quality control and regulatory standards
Germany – Europe’s Pharma Powerhouse
- Companies: Bayer, Boehringer Ingelheim
- Germany focuses on both bulk drug production and high-end medical research.
United Kingdom – Research and Exports
- Companies: GlaxoSmithKline (GSK), AstraZeneca
- Presence of Prestigious research institutions like Oxford
- UK played a major role during COVID-19 with Oxford vaccine collaboration
China – Global Leader in Bulk Drugs
- Dominates bulk drug and API manufacturing with large-scale, low-cost production
- Backed by strong government support under the “Made in China 2025” initiative
- Limitation: Still lags behind countries like the USA in original patent drug innovation
India – Generic Medicine Leader
- Major hubs: Hyderabad, Ahmedabad, Mumbai, Baddi, Sikkim, Vizag
- Known as the “Pharmacy of the Global South”
- Focus on generics, vaccines, and bulk drugs
India- Pharmacy of the Global South
India’s Position in Global Pharma
- Third largest producer of pharmaceuticals by volume
- Supplies over 60% of global demand for vaccines
- Accounts for 20% of global generic drug exports
- Major destinations: USA, Africa, EU
- Pharma exports: $25+ billion annually
- Employs over 3 million people (direct + indirect)
Pharma Industry Location in India
India is home to both global and domestic pharmaceutical giants such as Sun Pharma, Dr. Reddy’s, Cipla, Lupin, Biocon, Aurobindo Pharma, and Zydus Lifesciences.
Region/City | Highlights |
Hyderabad (Telangana) | – Known as the Bulk Drug Capital of India. – Also hosts R&D centres and global pharma companies like Dr. Reddy’s, Aurobindo, Divi’s, and Natco Pharma. – Home to the upcoming Hyderabad Pharma City, world’s largest integrated pharma cluster. |
Ahmedabad-Baroda (Gujarat) | – Companies like Zydus, Cadila, and Torrent Pharma operate here. |
Mumbai-Pune Belt (Maharashtra) | – Headquarters of several major companies like Cipla, Glenmark, and Lupin. – Strategic location with access to ports and international airports for exports. |
Baddi (Himachal) | – Hosts the largest number of pharmaceutical units in India. – Grew rapidly due to tax holidays and industrial incentives. – Contract manufacturing of pharmaceuticals happen here. |
Bengaluru (Karnataka) | – Biotech and pharma R&D hub. Home to Biocon and multiple biotech startups. |
Visakhapatnam (Andhra) | – Emerging API and bulk drug cluster. – Hosts Ramky Pharma City and upcoming Bulk Drug Park under PLI scheme. |
Sikkim | – Hub for formulation plants due to tax exemptions. Many companies shifted facilities here in 2000s. |
Indore, Nagpur (Central India) | – New pharma SEZs and industrial parks coming up. |
Why Is India Called the “Pharmacy of the Global South”?
India is globally recognized as the “Pharmacy of the Global South” — a title earned through its high-volume, low-cost production of generic medicines, crucial for public health systems in developing countries.
- Largest provider of generic drugs globally — exporting to over 200 countries, including Africa, Latin America, and Southeast Asia.
- Supplies over 60% of global vaccine demand (e.g., via Serum Institute of India).
- Plays a critical role in affordable access to life-saving medicines like antiretrovirals (HIV/AIDS), TB drugs, and malaria treatments.
- Supported countries through initiatives like Vaccine Maitri during COVID-19.
India supplying low-cost drugs to developing countries (Africa, LATAM) improves its image as a “Vishwaguru” and strategic partner.
Side Topic: What Are Generic Drugs?
Generic drugs are bioequivalent versions of branded medicines whose patents have expired. They have the same dosage, safety, strength, quality, and efficacy as the original, but are:
- Far cheaper
- Made without repeating expensive R&D
- Widely accepted under WHO and FDA standards
India’s pharma sector thrives on these, making healthcare accessible and affordable, especially in the Global South.
Government Initiatives to Promote Pharma Industry
1. Production-Linked Incentive (PLI) Scheme
- Under the PLI Scheme, companies get financial incentives for increasing their production over a set base year. Higher production compared to previous years = more incentive.
- In the pharma sector, this means: If a company manufactures important raw materials for medicines — like Active Pharmaceutical Ingredients (APIs) — in India instead of importing them, the government gives them a financial reward. This encourages companies to set up factories in India, create jobs, and reduce our dependence on countries like China for raw materials used in life-saving drugs.
2. Bulk Drug Parks
- Special zones in Himachal Pradesh, Tamil Nadu, and Andhra Pradesh for API manufacturing
- They benefit from state/central subsidies
3. 100% FDI via Automatic Route
- Attracts foreign capital and technology transfer
4. Jan Aushadhi Scheme
- Government initiative to provide low-cost generic drugs through Pradhan Mantri Bhartiya Jan Aushadhi Kendras
- Helps achieve universal health coverage
Challenges Faced by Indian Pharma Sector
- Overdependence on API Imports: India imports ~70% of its Active Pharmaceutical Ingredients (APIs), mainly from China. It creates vulnerability to global supply shocks and geopolitical tensions.
- Low Innovation Focus: Majority of Indian pharma companies rely on generic drug production. There is minimal investment in original drug discovery and patented molecules.
- Quality and Safety Concerns: Some small and medium manufacturers face criticism for inconsistent quality. Frequent inspections by USFDA and EU regulators, warning letters and import bans affect credibility and exports.
- Government Pricing Controls: The National Pharmaceutical Pricing Authority (NPPA) caps prices of essential drugs. It reduces profit margins and may discourage investment in R&D.